End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,798 ARS | +4.84% | +4.55% | +26.29% |
06:10pm | Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab | |
05:18pm | J&J: successful trial for Carvykti in multiple myeloma | CF |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an enterprise value anticipated at 3.95 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.29% | 356B | - | ||
+42.83% | 748B | C+ | ||
+34.11% | 598B | B | ||
+18.06% | 325B | B- | ||
+4.63% | 283B | C+ | ||
+17.02% | 245B | B+ | ||
+9.26% | 211B | B- | ||
-4.21% | 209B | A+ | ||
+2.43% | 166B | C+ | ||
+6.67% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ Stock
- Ratings Johnson & Johnson